BR0211227A - Composto, composição farmacêutica e seus usos - Google Patents

Composto, composição farmacêutica e seus usos

Info

Publication number
BR0211227A
BR0211227A BR0211227-2A BR0211227A BR0211227A BR 0211227 A BR0211227 A BR 0211227A BR 0211227 A BR0211227 A BR 0211227A BR 0211227 A BR0211227 A BR 0211227A
Authority
BR
Brazil
Prior art keywords
group
substituted
aryl group
independently
compound
Prior art date
Application number
BR0211227-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Keizo Koya
Lijun Sun
Shoujun Chen
Noriaki Tatsuta
Yaming Wu
Mitsunori Ono
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of BR0211227A publication Critical patent/BR0211227A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A45—HAND OR TRAVELLING ARTICLES
    • A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
    • A45D8/00—Hair-holding devices; Accessories therefor
    • A45D8/004—Hair-holding devices; Accessories therefor with decorative arrangements or form
    • A45D8/006—Interchangeable ornaments attached to hair holding devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
BR0211227-2A 2001-07-10 2002-07-10 Composto, composição farmacêutica e seus usos BR0211227A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30425201P 2001-07-10 2001-07-10
US36194602P 2002-03-06 2002-03-06
PCT/US2002/021717 WO2003006430A1 (en) 2001-07-10 2002-07-10 Taxol enhancer compounds

Publications (1)

Publication Number Publication Date
BR0211227A true BR0211227A (pt) 2004-08-10

Family

ID=26973915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211227-2A BR0211227A (pt) 2001-07-10 2002-07-10 Composto, composição farmacêutica e seus usos

Country Status (24)

Country Link
US (6) US6800660B2 (US07345094-20080318-C00031.png)
EP (3) EP1731148B1 (US07345094-20080318-C00031.png)
JP (1) JP4344235B2 (US07345094-20080318-C00031.png)
KR (2) KR101060079B1 (US07345094-20080318-C00031.png)
CN (1) CN100348580C (US07345094-20080318-C00031.png)
AT (2) ATE533483T1 (US07345094-20080318-C00031.png)
AU (1) AU2002316626B2 (US07345094-20080318-C00031.png)
BR (1) BR0211227A (US07345094-20080318-C00031.png)
CA (1) CA2455453C (US07345094-20080318-C00031.png)
CY (1) CY1105811T1 (US07345094-20080318-C00031.png)
DE (1) DE60214718T2 (US07345094-20080318-C00031.png)
DK (2) DK1406869T3 (US07345094-20080318-C00031.png)
ES (2) ES2395193T3 (US07345094-20080318-C00031.png)
HK (2) HK1060115A1 (US07345094-20080318-C00031.png)
IL (2) IL159773A0 (US07345094-20080318-C00031.png)
IS (1) IS2412B (US07345094-20080318-C00031.png)
MX (1) MXPA04000244A (US07345094-20080318-C00031.png)
NO (1) NO329457B1 (US07345094-20080318-C00031.png)
NZ (1) NZ530963A (US07345094-20080318-C00031.png)
PT (1) PT1406869E (US07345094-20080318-C00031.png)
SI (1) SI1406869T1 (US07345094-20080318-C00031.png)
TW (1) TWI332943B (US07345094-20080318-C00031.png)
WO (1) WO2003006430A1 (US07345094-20080318-C00031.png)
ZA (1) ZA200401051B (US07345094-20080318-C00031.png)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
AU2006228035B2 (en) * 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
JP5362986B2 (ja) * 2004-06-23 2013-12-11 シンタ ファーマスーティカルズ コーポレイション 癌治療のためのビス（チオ‐ヒドラジドアミド）塩
WO2006033913A2 (en) * 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
JP5204489B2 (ja) * 2004-11-19 2013-06-05 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ７０発現を増加するためのビス（チオ‐ヒドラジドアミド）
BRPI0610219A2 (pt) 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
WO2006113572A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
JP2008540658A (ja) * 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
WO2007021881A1 (en) * 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
TW200804307A (en) * 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
KR20090045354A (ko) 2006-08-21 2009-05-07 신타 파마슈티칼스 코프. 증식성 장애를 치료하기 위한 화합물
EP2059236A2 (en) * 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
JP2010501564A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫を治療するためのビス（チオヒドラジドアミド）
WO2008024301A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
TW200817348A (en) * 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007290490B2 (en) 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080118562A1 (en) * 2006-09-11 2008-05-22 Keizo Koya Bis(thiohydrazide amides) formulation
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
WO2008082579A1 (en) * 2007-01-03 2008-07-10 Synta Pharmaceuticals Corp. Method for treating cancer
WO2008136976A2 (en) * 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009020631A2 (en) 2007-08-07 2009-02-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009073148A2 (en) * 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
TW200940050A (en) * 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)
WO2009105257A1 (en) * 2008-02-21 2009-08-27 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
AU2009308511B2 (en) * 2008-10-22 2013-03-07 Synta Pharmaceutical Corp. Transition metal complexes of a bis[thiohydrazide amide] compound
WO2010048284A1 (en) 2008-10-22 2010-04-29 Synta Pharmaceuticals Corp. Transition metal complexes of bis[thiohydrazide amide] compounds
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
US8680100B2 (en) 2008-12-01 2014-03-25 Synta Pharmaceuticals Corp. Sulfonylhydrazide compounds for treating proliferative disorders
WO2011069159A2 (en) 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
AU2012335105A1 (en) 2011-11-10 2014-06-19 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
US20150057357A1 (en) 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US304252A (en) 1884-08-26 Gael behee
US304318A (en) 1884-09-02 Inlet-pipe for water-works
US361946A (en) 1887-04-26 Watch arbor and pivot
US3357956A (en) 1965-03-30 1967-12-12 Du Pont Polymeric 1, 3, 4-thiadiazoles and the process for their preparation
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (US07345094-20080318-C00031.png) * 1973-12-17 1975-07-21
US4822777A (en) 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP0693924B2 (en) 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
WO1995033710A1 (de) 1994-06-03 1995-12-14 Basf Aktiengesellschaft Carbamoylcarbonsäurehydrazide und ihre verwendung zur bekämpfung von schadpilzen
DE69604298T2 (de) * 1995-09-22 2000-05-18 Bioimage A/S, Soeborg Varianten des grünen fluoreszenzproteins, gfp
US5739686A (en) 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
KR980008219A (ko) 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
ES2202855T3 (es) * 1997-04-18 2004-04-01 Janssen Pharmaceutica Nv Uso de antagonistas 5ht3 para promover el lavado intestinal.
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
JP3099880B2 (ja) * 1998-08-12 2000-10-16 日本電気株式会社 半導体スイッチ及びスイッチ回路
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
JP3908876B2 (ja) * 1999-07-23 2007-04-25 日東電工株式会社 粘着テープ用基材フィルム及び粘着テープまたはシート
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
MXPA03006666A (es) * 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
CA2445967A1 (en) 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
WO2002094259A1 (en) 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20050154039A1 (en) 2001-11-28 2005-07-14 Marie-Odile Glacera Contour 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
JP4921162B2 (ja) 2003-02-11 2012-04-25 ヴァーナリス（ケンブリッジ）リミテッド 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
US20050288347A1 (en) 2004-03-26 2005-12-29 Hodge Carl N Certain triazole-based compounds, compositions, and uses thereof
JP5362986B2 (ja) 2004-06-23 2013-12-11 シンタ ファーマスーティカルズ コーポレイション 癌治療のためのビス（チオ‐ヒドラジドアミド）塩
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
JP5204489B2 (ja) 2004-11-19 2013-06-05 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ７０発現を増加するためのビス（チオ‐ヒドラジドアミド）
US20060167106A1 (en) 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
WO2006113572A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
JP2008540658A (ja) 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
WO2007021881A1 (en) 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2007267847B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
KR20090045354A (ko) 2006-08-21 2009-05-07 신타 파마슈티칼스 코프. 증식성 장애를 치료하기 위한 화합물
JP2010501564A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫を治療するためのビス（チオヒドラジドアミド）
EP2059236A2 (en) 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
WO2008024301A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
AU2007290490B2 (en) 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080118562A1 (en) 2006-09-11 2008-05-22 Keizo Koya Bis(thiohydrazide amides) formulation
EP2059250A2 (en) 2006-09-14 2009-05-20 Synta Pharmaceuticals Corporation Compounds for the treatment of angiogenesis
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
WO2008082579A1 (en) 2007-01-03 2008-07-10 Synta Pharmaceuticals Corp. Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009020631A2 (en) 2007-08-07 2009-02-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009073148A2 (en) 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
TW200940050A (en) 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)

Also Published As

Publication number Publication date
CY1105811T1 (el) 2011-02-02
TWI332943B (en) 2010-11-11
ATE339402T1 (de) 2006-10-15
US20080214655A1 (en) 2008-09-04
ATE533483T1 (de) 2011-12-15
EP2289876A1 (en) 2011-03-02
CN1553895A (zh) 2004-12-08
IL159773A (en) 2011-11-30
EP1731148B1 (en) 2011-11-16
NO20040095L (no) 2004-02-23
US7671092B2 (en) 2010-03-02
SI1406869T1 (sl) 2007-02-28
US9107955B2 (en) 2015-08-18
US20050009920A1 (en) 2005-01-13
CA2455453C (en) 2011-02-15
DK1731148T3 (da) 2012-02-27
CA2455453A1 (en) 2003-01-23
US20060122183A1 (en) 2006-06-08
CN100348580C (zh) 2007-11-14
US20030119914A1 (en) 2003-06-26
US7345094B2 (en) 2008-03-18
IL159773A0 (en) 2004-06-20
US20150344420A1 (en) 2015-12-03
PT1406869E (pt) 2007-01-31
US6800660B2 (en) 2004-10-05
US20100280075A1 (en) 2010-11-04
NO329457B1 (no) 2010-10-25
MXPA04000244A (es) 2005-03-07
WO2003006430A1 (en) 2003-01-23
DE60214718T2 (de) 2007-09-13
US7037940B2 (en) 2006-05-02
DK1406869T3 (da) 2007-01-22
IS2412B (is) 2008-10-15
KR101060079B1 (ko) 2011-08-29
ES2271292T3 (es) 2007-04-16
HK1101543A1 (en) 2007-10-18
NZ530963A (en) 2005-08-26
JP2004534848A (ja) 2004-11-18
ES2395193T3 (es) 2013-02-11
AU2002316626B2 (en) 2005-06-02
KR20040077650A (ko) 2004-09-06
EP1406869B1 (en) 2006-09-13
HK1060115A1 (en) 2004-07-30
ZA200401051B (en) 2005-08-31
KR20100066588A (ko) 2010-06-17
IS7101A (is) 2004-01-09
DE60214718D1 (de) 2006-10-26
EP1406869A1 (en) 2004-04-14
KR100990581B1 (ko) 2010-10-29
JP4344235B2 (ja) 2009-10-14
EP1731148A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
BR0211227A (pt) Composto, composição farmacêutica e seus usos
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
EP1496076A4 (en) HYDROPHILIC Y-BRANCH POLYMER DERIVATIVE AND METHOD OF MANUFACTURING THEREOF; ABOVE CONNECTED MEDICAL COMPOSITE
BRPI0512526A (pt) composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
TWI268279B (en) Dimeric anti-viral agents and methods for preparation and use thereof
BR0010555A (pt) Inibidores de neuraminidases
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
BRPI0517619A (pt) entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
BRPI0606367A2 (pt) derivados espirocetais e composições farmacêuticas compreendendo os mesmos
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
ATE532790T1 (de) Einschlussverbindung mit cucurbiturilderivaten als wirtsmolekül, und diese enthaltende pharmazeutische zusammensetzung
BR0102607A (pt) Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
ATE114459T1 (de) Polyasparaginsäurederivate als überzugsmittel für arzneiformen und lebensmittel.
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto
BRPI0518117A (pt) uso de um derivado de piridotienopirimidina, composição farmacêutica, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]